High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities

ConclusionsSmall sub-sets of breast cancers with high TMB exist and may present an opportunity for effective immunotherapeutic targeting.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - Category: Internal Medicine Authors: Source Type: research
New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - Category: Internal Medicine Authors: Source Type: research
FoundationOne CDx has earned yet another approval from FDA, making the companion diagnostic now available for 19 FDA-approved targeted therapies. It can now be used as a companion diagnostic for Piqray (alpelisib) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. FDA approved Piqray in May 2019, and it is the first and only treatment specifically for patients with a PIK3CA mutation i...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Source Type: news
Roche today announced new data from the phase III FeDeriCa study which showed the investigational fixed-dose combination (FDC) of Perjeta ® (pertuzumab) and Herceptin® (trastuzumab), administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) and comparable efficacy and safety to standard IV infusions of Perjeta plus Hercep tin and chemotherapy in eligible people with HER2-positive early breast cancer (eBC).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
In heavily pretreated patients, adding tucatinib versus placebo improves overall, progression - free survival
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Gynecology, Neurology, Oncology, Pharmacy, Conference News, Source Type: news
Publication date: 10 December 2019Source: Cell Reports, Volume 29, Issue 11Author(s): William W. Feng, Owen Wilkins, Scott Bang, Matthew Ung, Jiaqi Li, Jennifer An, Carmen del Genio, Kaleigh Canfield, James DiRenzo, Wendy Wells, Arti Gaur, R. Brooks Robey, Jessie Yanxiang Guo, Ryan L. Powles, Christos Sotiriou, Lajos Pusztai, Maria Febbraio, Chao Cheng, William B. Kinlaw, Manabu KurokawaSummaryAlthough it is established that fatty acid (FA) synthesis supports anabolic growth in cancer, the role of exogenous FA uptake remains elusive. Here we show that, during acquisition of resistance to HER2 inhibition, metabolic rewiring...
Source: Cell Reports - Category: Cytology Source Type: research
A new analysis some 6 years after randomization continues to support dual HER2 blockade plus chemotherapy for HER2-positive early breast cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
A study led by UCLA researchers found that adding ribociclib, a targeted therapy drug, to standard hormone therapy significantly improves overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer, one of the most common types of the disease.The findings also show the combination treatment is beneficial at the time of recurrence and should become a first-line option in postmenopausal women with HR+/HER2- advanced breast cancer.The study was published today in the New England Journal of Medicine and presented earlier this year at the European Society for Medical Oncology Congress in...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Women with HER2-positive breast cancer may soon have some brand new treatment options after two experimental drugs performed well in clinical trials.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
The investigational oral therapy tucatinib, when added to standard trastuzumab and capecitabine, resulted in a"clinically meaningful" lower risk of disease progression or death compared with placeboMedscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Gastroschisis Repair | HER2 | Immunotherapy | Study